YU18597A - Inhibitori matričnih metaloproteinaza, supstituisane biaril oksibuterne kiseline - Google Patents

Inhibitori matričnih metaloproteinaza, supstituisane biaril oksibuterne kiseline

Info

Publication number
YU18597A
YU18597A YU18597A YU18597A YU18597A YU 18597 A YU18597 A YU 18597A YU 18597 A YU18597 A YU 18597A YU 18597 A YU18597 A YU 18597A YU 18597 A YU18597 A YU 18597A
Authority
YU
Yugoslavia
Prior art keywords
disease
compounds
conditions
pharmaceutical compositions
oxobuteric
Prior art date
Application number
YU18597A
Other languages
English (en)
Inventor
Zandt Michael C. Van
David R. Brittelli
Brian R. Dixon
Original Assignee
Bayer Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corporation filed Critical Bayer Corporation
Publication of YU18597A publication Critical patent/YU18597A/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44Two oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/76Unsaturated compounds containing keto groups
    • C07C59/90Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/041,2,3-Triazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Jedinjenja inhibicije matricne metaloproteaze, njihovi farmaceutski preparati i postupak tretiranja obolenja koji koristi takva jedinjenja su prezentirani. Jedinjenja iz pronalaska imaju opste formule: gde r je 0-2, T je odabran od i R40 je mono- ili bi-heterociklicna struktura. Ova jedinjenja su korisna za inhibiciju matricne metaloproteaze i, zato, se bore protiv stanja kojima MMP doprinose, takvim kao osteoartritis, reumatodini artritis, septicni artritis, periodontalno obolenje, kornealna ulceracija, proteinurija, aneurizmalno aortno obolenje, distrofobna epidermoliza, bulosa, stanja koja dovode do inflamatornih odgovora, osteopeniaza izazvane pomocu MMP aktivnosti, tempero mandibularno zglobno obolenje, demielaciona obolenja nervnog sistema, tumorna metastaza ili degenerativni gubitak zglobne hrskavice koji prati traumatsku povredu zgloba, i koronarna tromboza usled ateroskleroticnog platelatnog pucanja. Ovaj pronalazak takode obezbeduje famaceutski preparat i postupke za tretiranje takvih stanja.
YU18597A 1996-05-15 1997-05-12 Inhibitori matričnih metaloproteinaza, supstituisane biaril oksibuterne kiseline YU18597A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64849396A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
YU18597A true YU18597A (sh) 2001-12-26

Family

ID=24601014

Family Applications (1)

Application Number Title Priority Date Filing Date
YU18597A YU18597A (sh) 1996-05-15 1997-05-12 Inhibitori matričnih metaloproteinaza, supstituisane biaril oksibuterne kiseline

Country Status (25)

Country Link
EP (1) EP0923530B1 (sh)
JP (1) JP3354942B2 (sh)
CN (1) CN1100748C (sh)
AR (1) AR007098A1 (sh)
AT (1) ATE275123T1 (sh)
AU (1) AU714207B2 (sh)
BR (1) BR9709086A (sh)
CA (1) CA2254731C (sh)
CO (1) CO5011061A1 (sh)
DE (1) DE69730508T2 (sh)
DK (1) DK0923530T3 (sh)
ES (1) ES2227696T3 (sh)
HK (1) HK1021897A1 (sh)
HR (1) HRP970244B1 (sh)
ID (1) ID17291A (sh)
MY (1) MY132463A (sh)
PA (1) PA8429701A1 (sh)
PE (1) PE66898A1 (sh)
PT (1) PT923530E (sh)
SV (1) SV1997000036A (sh)
TN (1) TNSN97083A1 (sh)
TW (1) TW539672B (sh)
WO (1) WO1997043239A1 (sh)
YU (1) YU18597A (sh)
ZA (1) ZA974030B (sh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925637A (en) * 1997-05-15 1999-07-20 Bayer Corporation Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
EP1031349A1 (en) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
GB9922710D0 (en) * 1999-09-24 1999-11-24 Bayer Ag Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
JP2004359546A (ja) * 2001-03-15 2004-12-24 Ono Pharmaceut Co Ltd ヒドロキサム酸誘導体、それらの非毒性塩およびそれらのプロドラッグ体を有効成分として含有する、固形癌の予防および/または治療剤
WO2002074298A1 (fr) * 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Inhibiteurs de production d'il-6
KR101405823B1 (ko) * 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US20120040974A1 (en) * 2008-08-18 2012-02-16 Yale University Mif modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
CN106458938A (zh) 2014-04-03 2017-02-22 拜耳制药股份公司 手性2,5‑二取代的环戊烷甲酸衍生物及其用途
EP3126339A1 (de) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
CA2944614A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases
CN113979992B (zh) * 2021-11-19 2022-06-24 西安欧得光电材料有限公司 一种3-取代二苯并噻吩及其合成方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0905126B1 (en) * 1994-01-22 2002-12-04 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors

Also Published As

Publication number Publication date
ATE275123T1 (de) 2004-09-15
HK1021897A1 (en) 2000-07-14
CA2254731C (en) 2004-07-20
PE66898A1 (es) 1998-10-22
ZA974030B (en) 1998-02-19
DK0923530T3 (da) 2005-01-03
TNSN97083A1 (fr) 2005-03-15
ID17291A (id) 1997-12-18
ES2227696T3 (es) 2005-04-01
DE69730508D1 (de) 2004-10-07
AR007098A1 (es) 1999-10-13
BR9709086A (pt) 1999-08-03
JP3354942B2 (ja) 2002-12-09
AU714207B2 (en) 1999-12-23
CN1100748C (zh) 2003-02-05
TW539672B (en) 2003-07-01
HRP970244B1 (en) 2005-06-30
CN1225621A (zh) 1999-08-11
JPH11510821A (ja) 1999-09-21
HRP970244A2 (en) 1998-04-30
EP0923530A1 (en) 1999-06-23
DE69730508T2 (de) 2005-09-29
PT923530E (pt) 2004-12-31
CA2254731A1 (en) 1997-11-20
CO5011061A1 (es) 2001-02-28
EP0923530B1 (en) 2004-09-01
WO1997043239A1 (en) 1997-11-20
SV1997000036A (es) 1998-07-20
PA8429701A1 (es) 2000-05-24
MY132463A (en) 2007-10-31
AU3122097A (en) 1997-12-05

Similar Documents

Publication Publication Date Title
YU18597A (sh) Inhibitori matričnih metaloproteinaza, supstituisane biaril oksibuterne kiseline
ATE231490T1 (de) Hydroxamsäurederivate zur verwendung in der behandlung von bindegewebserkrankungen
ID18143A (id) Penghambat metaloprotease amina siklik tersubstitusi
IS4031A (is) Hydroxamicsýruafleiður, aðferð til framleiðslu þeirra og notkunar sem lyfja
WO1996040745A3 (en) Amino acid amides of 5-amino-1,3,4-thiadiazones and their use as inhibitors for matrix metalloproteinases
EP1163208A4 (en) CASPASE INHIBITORS AND THEIR USE
NZ511885A (en) 2,3,4,5-tetrahydro-1H-[1,4]benzodiazephine-3-hydroxamic acid as matrix metalloproteinase inhibitors and as inhibitors of TNF-alpha converting enzyme (TACE)
NO990896L (no) Bidentate metalloproteaseinhibitorer
SE9704653L (sv) Förfarande för behandling av avfallsslam
DE69811360D1 (de) Diazepinoindolone als phophodiesterase 4 inhibitoren
DE69723258T2 (de) Thiadiazolyl(thio)harnstoffe und ihre verwendung als matrix-metallprotease inhibitoren
YU18497A (sh) Matrično-metaloproteazno inhibirajuća jedinjenja, supstituisana fenetil jedinjenja
TNSN97084A1 (fr) Biaryl acetylenes comme inhibiteurs des matrices metalloproteinases
YU67900A (sh) Sukcinamidni inhibitori interleukin-1beta konvertujućeg enzima
CA2254750A1 (en) Inhibition of matrix metalloproteases by 2-(.omega.-aroylalkyl)-4-biaryl-oxobutyric acids
PT1134215E (pt) Compostos hidroxamidas do acido 2-oxo-imidazolidino-4-carboxilico que inibem metaloproteinases de matriz
HUP0102243A2 (hu) sPLA2-inhibitor vegyületek betegség kezelésére
TNSN97085A1 (fr) Substitution oxybuterique des acides comme inhibiteurs de la matrice metalloprotease
ECSP972113A (es) Inhibicion de las metaloproteasas de matriz por acidos biariloxobutiricos sustituidos
ECSP972112A (es) Inhibicion de las metaloproteasas de matriz por compuestos de fenetilo sustituido
ECSP972114A (es) Biarilacetilenos como inhibidores de la metaloproteasa de matriz
ECSP972111A (es) Inhibidores de la metaloproteinasas de matriz por acidos 2-(aroilalquil)-4 biaril-4- oxobutiricos
TH12333B (th) การยับยั้งแมทริกซ์เมธัลลอโปรตีเนสโดยสารประกอบซับสทิทิวเทดเฟเนธิล
ECSP972115A (es) Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz
WO2000019989A3 (de) Verwendung von katecholderivaten als proteinaseinhibitoren